Black Diamond Therapeutics, Inc. ( (BDTX) ) has released its Q3 earnings. Here is a breakdown of the information Black Diamond Therapeutics, ...
Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be ...
CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of ...
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of ...
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Black Diamond Therapeutics, Inc. (BDTX) on Tuesday reported a loss of $15.6 million in its third quarter. The Cambridge, Massachusetts-based company ...
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest ...
(MENAFN- GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology ...
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback